Introduction to Observational Retrospective
Sentence Examples
Discover more insights into Observational Retrospective
Keywords frequently search together with Observational Retrospective
Narrow sentence examples with built-in keyword filters
Observational Retrospective sentence examples within case control study
STUDY DESIGN
A single-center observational retrospective case-control study was performed by reviewing medical records, cCTG databases and pathological reports of women with singleton pregnancy and IUGR uncomplicated (controls) and complicated by preeclampsia (cases).
Full Text
Methods This observational retrospective case-control study reviewed 308 patients who received surgical treatment of FSF between January 2016 and October 2020 at a university hospital.
Full Text
Observational Retrospective sentence examples within intensive care unit
Methods An observational retrospective cohort study using intensive care unit (ICU) admissions of Medical Information Mart for Intensive Care III from the Beth Israel Deaconess Medical Center in Boston, MA, USA between 2001 and 2012 was conducted.
Full Text
This observational retrospective study aimed to investigate the usefulness of Sequential Organ Failure Assessment (SOFA), Quick SOFA (qSOFA), National Early Warning Score (NEWS), and quick NEWS in predicting respiratory failure and death among patients with COVID-19 hospitalized outside of intensive care units (ICU).
Full Text
Observational Retrospective sentence examples within cross sectional study
Patients and Methods This paper presents an observational retrospective cross-sectional study to determine the association between continuous daily taking low-dose aspirin (50–100mg) for more than one month and SUA with fraction excretion of uric acid (FEUA) in elderly patients.
Full Text
CLINICAL RELEVANCE
This observational retrospective cross-sectional study failed to associate mandibular fracture lines with the presence of dental implants.
Full Text
Learn more from Observational Retrospective
Observational Retrospective sentence examples within single center study
Observational Retrospective sentence examples within real life study
Observational Retrospective sentence examples within coronavirus disease 2019
Methods This was an observational retrospective study of hospitalized adult patients with confirmed coronavirus disease 2019 (COVID-19).
Full Text
In this observational retrospective study, we report our experience on all elderly patients with ascertained diagnosis of coronavirus disease 2019 through nasopharyngeal swab with real time-polymerase chain reaction at our Pugliese-Ciaccio hospital in Catanzaro, who received hydroxychloroquine (HCQ), with or without azithromycin (AZY).
Full Text
Observational Retrospective sentence examples within tertiary care hospital
Materials and Methods: An observational retrospective study was carried out from the laboratory records of consecutive 208 patients admitted to the tertiary care hospital between March 2020 to May 2020.
Full Text
Methods This observational retrospective study was conducted in consecutive patients with COVID-19 pneumonia admitted to a tertiary care hospital in Modena, Italy.
Full Text
Observational Retrospective sentence examples within 2 infection treated
Methods: We performed an observational retrospective cohort study, including admitted patients with suspected SARS-CoV-2 infection, treated according to medical criteria and local protocols based on the best available scientific evidence.
Full Text
METHODS
We performed an observational retrospective cohort study, including admitted patients with suspected SARS-CoV-2 infection, treated according to medical criteria and local protocols based on the best available scientific evidence.
Full Text
Observational Retrospective sentence examples within 12 5 %
Background and importanceMultiple sclerosis (MS) secondline disease modifying treatments (DMT) cause lymphocyte or B cell depletion, such as therapy with natalizumab, ocrelizumab, alemtuzumab or rituximab They can present a varying degree of immunodeficiency that can translate into an increased risk of infections The decision making process should balance the risks of stopping an active treatment and the risk of COVID-19 infection Aim and objectivesTo evaluate the management of MS patients with secondline DMT via infusion with natalizumab, ocrelizumab, rituximab and alemtuzumab during the COVID-19 pandemic Material and methodsAn observational retrospective study was conducted between January 2020 and October 2020 of MS patients on active treatment with natalizumab, ocrelizumab, rituximab or alemtuzumab who were expected to receive new dosages in this period For data collection, the electronic clinic history system (Selene) and the programme Farmatools were used Variables collected were: sex, age, expanded disability status scale (EDSS), COVID-19 diagnosis and type of MS Treatment changes/delays due to COVID-19 were reviewed In case of delay, the number of days was quantified Results40 patients (65% women) treated with different infusion therapies were evaluated with a median age of 47 3 (SD 13,3) The average EDSS was 3 8 (SD 2 1) 29 patients had relapsing–remitting MS (72,5%), 7 had primary progressive MS (17 5%) and 4 had secondary progressive MS (10%) Five (12 5%) COVID-19 cases were diagnosed No delays were registered in 13 infusions of natalizumab;2 patients, due to a suboptimal response, were changed to ocrelizumab, reducing hospital visits, and one was transferred to another hospital Three patients were expected to receive alemtuzumab No one received alemtuzumab and two were changed to ocrelizumab due to the European Medicines Agency (EMA) alert that recommended restricting the use of alemtuzumab during the COVID-19 pandemic Two patients received rituximab in time;one was changed to natalizumab due to infusion reactions and in one case the dosing interval was extended to 36 days Eight patients began ocrelizumab treatment, eight received their dose without delay, one died and in five cases the dosing interval was extended to 39 days (SD 23 8) Conclusion and relevanceAccording to the recommendations, a case-by-case analysis should be performed, but it seems that the COVID-19 pandemic has conditioned MS treatments as changes/delays were registered Five (12 5%) COVID-19 cases were diagnosed, similar to the outcomes obtained in the seroprevalence study in the same region References and/or acknowledgementsConflict of interestNo conflict of interest.
Full Text
Background and importanceBaricitinib is an immunosuppressive agent included as one of the therapeutic options for COVID-19 in the Spanish protocol Agencia Española del Medicamento y Productos Sanitarios Aim and objectivesThe objective was to assess the effectiveness of this drug in hospitalised but non-critically ill patients Material and methodsAn observational retrospective study was conducted in a third level hospital from 26 March to 5 May Inclusion criteria were: hospitalised patients diagnosed with COVID-19 pneumonia and treated with baricitinib Data collected were: age, gender, comorbidities, severe pneumonia diagnosis, ferritin and interleukin 6 (IL-6) prior to the beginning of treatment with baricitinib, standard of care according to the hospital’s protocol, concomitant treatment with anakinra, duration of treatment with baricitinib, average hospital stay (AHS), deaths and hospital discharges The data were collected from the electronic medical records and the hospital’s management department Results171 patients treated with baricitinib were included, with an average age of 69 5 (34–96) years 71 3% (122) were men 87 1% (149) had comorbidities and 73 1% (125) were diagnosed with a severe pneumonia, with 25% of them dying (31) Median duration of treatment with baricitinib was 5 days (1–12) AHS for the baricitinib group was 14 60 (3–47) days, and AHS for the whole sample of patients diagnosed with COVID-19 pneumonia was 17 2 days 23 4% (40) of patients had high levels of ferritin (>2500 UI/L) Among them, 87 5% (35) were discharged and 12 5% (5) died IL-6 levels were high (>40 U/L) in 29 8% (51) of patients, 40 UI/L Hence IL-6 level appears to be a better prognostic factor of mortality than ferritin This could also be related to a greater patient’s immune response Regarding treatment effectiveness, mortality of patients who were treated with SoC plus baricitinib was similar to that of patients treated with anakinra plus baricitinib References and/or acknowledgementsConflict of interestNo conflict of interest.
Full Text
Observational Retrospective sentence examples within 19 patients admitted
METHODOLOGY
This was a single-center observational retrospective cohort study that enrolled COVID-19 patients admitted to the "Martyrs medical military complex- COVID Hospital" in Palestine.
Full Text
This is a single-center observational retrospective study that included 29 consecutive COVID-19 patients admitted to the San Matteo Hospital Foundation between February and May 2020, with a diagnosis of PE, and a control population of 23 non-COVID-19 patients admitted at our hospital during the same time lapse in 2019.
Full Text
Observational Retrospective sentence examples within 5 days later
Background and importanceTocilizumab is being used to treat severe SARS-CoV-2 pneumonia Aim and objectivesTo analyse the efficacy of tocilizumab in patients with severe SARS-CoV-2 pneumonia during the inflammatory phase of the disease Material and methodsAn observational retrospective study was conducted between 16 March and 22 April 2020, which included 75 patients (57 men, mean age 67 7 years) treated with tocilizumab Criteria for severe pneumonia were: failure of at least one organ, oxygen saturation with ambient air <90% or respiratory rate ≥30 breaths per minute Prognosis at admission was evaluated with the CURB-65 score An analysis was performed with SPSS V 23 0 To evaluate efficacy, the variation in C reactive protein (CRP) and lymphocyte count (LC) was measured from the time before tocilizumab treatment until 5 days later, in all patients and separately in those who remained alive and those who died Results75% of patients had a CURB-65 score ≤2 on admission Mean time from onset of symptoms to treatment with tocilizumab was 11 6 days 17 patients were admitted to the intensive care unit Mean hospital stay was 19 7 days During admission, all patients previously received lopinavir–ritonavir and hydroxychloroquine, 67 high dose corticosteroids, 6 baricitinib and 15 interferon-beta-1b 19 patients (25%) died Mean CRP before tocilizumab treatment was 154 1 mg/L (95% CI 129 0 to 179 0) versus a mean of 15 2 mg/L (95% CI 8 6 to 21 4) 5 days later In patients who remained alive, the mean CRP decreased from 163 4 mg/L (95% CI 134 5 to 192 3) to 13 1 mg/L (95% CI 8 9 to 17 3), and in those who died, it decreased from 117 6 mg/L (95% CI 69 9 to 165 2) to 23 2 mg/L (95% CI 0 0 to 52 0) Mean LC before tocilizumab treatment was 1080/μL (95% CI 360 to 1790) versus a mean LC of 1690/μL (95% CI 530 to 2860) 5 days later In patients who remained alive, the mean LC increased from 1180/μL (95% CI 280 to 2080) to 1810/μL (95% CI 350 to 3270), and in those who died it increased from 680/μL (95% CI 550 to 810) to 1220/μL (95% CI 740 to 1700) Conclusion and relevanceIn patients with severe SARS-CoV-2 pneumonia, we found a significant decrease in CRP and an increase in LC associated with treatment with tocilizumab in the inflammatory phase of the disease Both variations were greater in patients who remained alive LC prior to treatment with tocilizumab was lower in those who died than in living patients References and/or acknowledgementsConflict of interestNo conflict of interest.
Full Text
Observational Retrospective sentence examples within An Observational Retrospective
Design: An observational retrospective cohort study from 178 hospitals from a large health system across the United States.
Full Text
Methods: An observational retrospective and prospective study between 2018 and 2020 was conducted in the Department of Medical Oncology at Tata Memorial Hospital, Mumbai, India.
Full Text
Observational Retrospective sentence examples within Center Observational Retrospective
STUDY DESIGN
A single-center observational retrospective case-control study was performed by reviewing medical records, cCTG databases and pathological reports of women with singleton pregnancy and IUGR uncomplicated (controls) and complicated by preeclampsia (cases).
Full Text
Methods In this single-center observational retrospective study, authors reviewed data of 75 meningioma patients confirmed by the WHO histological grades (WHO I/II/III) which were underwent CT scans from January 1, 2005 to December 30, 2019 at a teaching hospital, in XXXX.
Full Text
Observational Retrospective sentence examples within Multicenter Observational Retrospective
Methods and Results This international multicenter observational retrospective study collected information for all patients from 16 high‐volume hospitals who were treated with MitraClip after failed SMVR from October 29, 2009, until August 1, 2017.
Full Text
Materials and Methods This multicenter observational retrospective cohort study (ClinicalTrials.
Full Text
Observational Retrospective sentence examples within Methodsan Observational Retrospective
Background and importanceMultiple sclerosis (MS) secondline disease modifying treatments (DMT) cause lymphocyte or B cell depletion, such as therapy with natalizumab, ocrelizumab, alemtuzumab or rituximab They can present a varying degree of immunodeficiency that can translate into an increased risk of infections The decision making process should balance the risks of stopping an active treatment and the risk of COVID-19 infection Aim and objectivesTo evaluate the management of MS patients with secondline DMT via infusion with natalizumab, ocrelizumab, rituximab and alemtuzumab during the COVID-19 pandemic Material and methodsAn observational retrospective study was conducted between January 2020 and October 2020 of MS patients on active treatment with natalizumab, ocrelizumab, rituximab or alemtuzumab who were expected to receive new dosages in this period For data collection, the electronic clinic history system (Selene) and the programme Farmatools were used Variables collected were: sex, age, expanded disability status scale (EDSS), COVID-19 diagnosis and type of MS Treatment changes/delays due to COVID-19 were reviewed In case of delay, the number of days was quantified Results40 patients (65% women) treated with different infusion therapies were evaluated with a median age of 47 3 (SD 13,3) The average EDSS was 3 8 (SD 2 1) 29 patients had relapsing–remitting MS (72,5%), 7 had primary progressive MS (17 5%) and 4 had secondary progressive MS (10%) Five (12 5%) COVID-19 cases were diagnosed No delays were registered in 13 infusions of natalizumab;2 patients, due to a suboptimal response, were changed to ocrelizumab, reducing hospital visits, and one was transferred to another hospital Three patients were expected to receive alemtuzumab No one received alemtuzumab and two were changed to ocrelizumab due to the European Medicines Agency (EMA) alert that recommended restricting the use of alemtuzumab during the COVID-19 pandemic Two patients received rituximab in time;one was changed to natalizumab due to infusion reactions and in one case the dosing interval was extended to 36 days Eight patients began ocrelizumab treatment, eight received their dose without delay, one died and in five cases the dosing interval was extended to 39 days (SD 23 8) Conclusion and relevanceAccording to the recommendations, a case-by-case analysis should be performed, but it seems that the COVID-19 pandemic has conditioned MS treatments as changes/delays were registered Five (12 5%) COVID-19 cases were diagnosed, similar to the outcomes obtained in the seroprevalence study in the same region References and/or acknowledgementsConflict of interestNo conflict of interest.
Full Text
Background and importanceBaricitinib is an immunosuppressive agent included as one of the therapeutic options for COVID-19 in the Spanish protocol Agencia Española del Medicamento y Productos Sanitarios Aim and objectivesThe objective was to assess the effectiveness of this drug in hospitalised but non-critically ill patients Material and methodsAn observational retrospective study was conducted in a third level hospital from 26 March to 5 May Inclusion criteria were: hospitalised patients diagnosed with COVID-19 pneumonia and treated with baricitinib Data collected were: age, gender, comorbidities, severe pneumonia diagnosis, ferritin and interleukin 6 (IL-6) prior to the beginning of treatment with baricitinib, standard of care according to the hospital’s protocol, concomitant treatment with anakinra, duration of treatment with baricitinib, average hospital stay (AHS), deaths and hospital discharges The data were collected from the electronic medical records and the hospital’s management department Results171 patients treated with baricitinib were included, with an average age of 69 5 (34–96) years 71 3% (122) were men 87 1% (149) had comorbidities and 73 1% (125) were diagnosed with a severe pneumonia, with 25% of them dying (31) Median duration of treatment with baricitinib was 5 days (1–12) AHS for the baricitinib group was 14 60 (3–47) days, and AHS for the whole sample of patients diagnosed with COVID-19 pneumonia was 17 2 days 23 4% (40) of patients had high levels of ferritin (>2500 UI/L) Among them, 87 5% (35) were discharged and 12 5% (5) died IL-6 levels were high (>40 U/L) in 29 8% (51) of patients, 40 UI/L Hence IL-6 level appears to be a better prognostic factor of mortality than ferritin This could also be related to a greater patient’s immune response Regarding treatment effectiveness, mortality of patients who were treated with SoC plus baricitinib was similar to that of patients treated with anakinra plus baricitinib References and/or acknowledgementsConflict of interestNo conflict of interest.
Full Text
Observational Retrospective sentence examples within Method Observational Retrospective
Methods Observational retrospective study obtaining clinical data from the electronic health records of patients who were followed-up by SARS-CoV-2 possible infection in a primary care practice in Madrid.
Full Text
Introduction and objectives Individuals with Chronic Obstructive Pulmonary Disease (COPD) have increased risk of severe pneumonia and poor outcomes when they develop severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Hoffmann 2020) We hypothesised that there would be a difference in survival and length of stay between COPD phenotypes with SARS-CoV-2 infections requiring hospital admission Methods Observational retrospective analysis of individuals admitted to a teaching hospital was performed on during the first peak of the SARS-CoV-2 pandemic (1st March to 30th June 2020) Individuals with COPD were identified and grouped into phenotypes;frequent exacerbators (-2 severe exacerbations in the last 12 months), emphysemapredominant, chronic bronchitis (cough and sputum production) and eosinophilic-predominant (plasma eosinophil count-300 cells/mL) Overall survival and length of stay for all phenotypes was compared using Kaplan-Meier methodology Results 508 individuals were admitted to hospital with SARS-CoV-2 infection during this time period 55 (11%) of these individuals had a diagnosis of COPD Survival was significantly lower in all individuals with SARS-CoV-2 infection (34%) compared to individuals with SARS-CoV-2 infection and co-existing COPD (58%) (p = 0 0003) There was no difference between baseline characteristics (age, gender and smoking status) between all COPD phenotypes There was no significant difference in survival between all 4 phenotypes;median survival for frequent exacerbators, emphysema-predominant, chronic bronchitis and eosinophiliapredominant (113 vs 7 vs 39 vs 36 respectively), X2 (2) = 3 9, p = 0 3;figure 1A There was no difference in length of stay between all commers 13 days and individuals with COPD 12 5 days (p = 1 0) There was no significant difference in length of stay between all 4 phenotypes;median length of stay for frequent exacerbators, emphysema-predominant, chronic bronchitis and eosinophilia-predominant (12 vs 9 vs 13 vs 14 respectively), X2 (2) = 3 0, p = 0 4;figure 1B Conclusions These data do not support the hypothesis that COPD phenotype would result in a difference in a difference in survival and length of stay Further study should investigate factors which predict survival of SARS-CoV-2 infection in individuals with co-existent COPD in a larger population.
Full Text
Observational Retrospective sentence examples within Descriptive Observational Retrospective
Observational Retrospective sentence examples within Multicentre Observational Retrospective
Methods and analysis The TRANSCOV cohort is a multicentre observational retrospective study.
Full Text
We performed a multicentre observational retrospective cohort study for comparing invasive procedures for prenatal diagnosis performed during the trimester March–May 2020 to those performed during the same trimester of the year 2019.
Full Text
Observational Retrospective sentence examples within Centre Observational Retrospective
Observational Retrospective sentence examples within My Observational Retrospective
Our observational retrospective study showed that men and women in their 50s and 40s respectively tend to delay their call for help from symptoms onset.
Full Text
Our observational retrospective multicenter study enrolled 33 SSc women with a personal history of BC identified at two Rheumatology/SSc Units in the north of Italy between January 2017 and December 2019 (lc/dcSSc 23/9, 1 unknown; mean age at SSc onset 57 years, range 32-73).
Full Text
Observational Retrospective sentence examples within Longitudinal Observational Retrospective
Observational Retrospective sentence examples within Month Observational Retrospective
This study is a 6-month observational retrospective study in two care facilities in Brussels: an academic general hospital and an academic oncology center.
Full Text
Material and methods In this 6 month observational retrospective study (January to June 2020), based on patient interviews, we obtained demographic parameters, reduced monthly migraine days (RDMM), a response rate of 50% (TR50) and adverse effects during treatment.
Full Text
Observational Retrospective sentence examples within Multicentric Observational Retrospective
Methods: In this multicentric observational retrospective study, we enrolled patients over 18 years old admitted for AIS in 3 stroke units of the Parisian region during lockdown from March 17, 2020, to May 2, 2020.
Full Text
This multicentric observational retrospective study included 1339 couples who underwent 2759 IVF-ICSI cycles using autologous oocytes from January 2000 to March 2019.
Full Text
Observational Retrospective sentence examples within Sectional Observational Retrospective
Objectives: This cross-sectional observational retrospective study aimed at assessing the cephalometric skeleto-dental features of class I, II, and III skeletal relationships of Saudi female school children samples and comparing the results to the established North American Caucasian cephalometric standards.
Full Text
Materials and Methods: This was a 4-year cross-sectional observational retrospective and prospective study of 47 cases of gastric carcinomas.
Full Text
Observational Retrospective sentence examples within Present Observational Retrospective
Simple random sampling and sampling based on prescription errors that were identified, documented, and reported before reaching the patients in the first three quarters of 2017 were performed in present observational retrospective study.
Full Text
The present observational retrospective study aimed to evaluate the mean daily dose of nilotinib prescribed as first- and second-line therapy among patients suffering from chronic myeloid leukemia (CML) in settings of clinical practice in Italy.
Full Text
Observational Retrospective sentence examples within observational retrospective study
METHODS
This observational retrospective study was performed in a Spanish tertiary hospital and included men with chemotherapy-naïve mCPRC who started treatment with abiraterone or enzalutamide between September 2012 and November 2018.
Full Text
This was an observational retrospective study of adult patients who were diagnosed with GBS during that time.
Full Text
Observational Retrospective sentence examples within observational retrospective cohort
We conducted an observational retrospective cohort study of 1200 women ≥ 18 years old undergoing gynecologic surgery for benign, possibly benign, or malignant indications on a gynecologic oncology service at a university medical center from 2009-2016.
Full Text
Observational Retrospective sentence examples within observational retrospective case
STUDY DESIGN
A single-center observational retrospective case-control study was performed by reviewing medical records, cCTG databases and pathological reports of women with singleton pregnancy and IUGR uncomplicated (controls) and complicated by preeclampsia (cases).
Full Text
Methods This was an observational retrospective case–control study based on patients hospitalized between 1 March and 15 April 2020 with SARS-CoV-2 infection and AKI.
Full Text
Observational Retrospective sentence examples within observational retrospective analysi
Methods: This is an observational retrospective analysis of medical records maintained for advanced cancer patients who have been enrolled in home-based palliative care services.
Full Text
Method: An observational retrospective analysis from a prospectively maintained database was performed in our department.
Full Text